Cartalax

The references section of this page cites 5 primary papers published between 2014 and 2020 — a limited but non-trivial record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.

Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for Cartalax, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.

Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.

Verification for Cartalax is per lot, not per product. The current 20mg lot CART-CA-26F-20 returned 99.784% purity, 20.64 mg measured, 103.2% of the labelled 20 mg, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.

Purity is half the number. It states what fraction of the material in the vial is Cartalax; it says nothing about how much material is in the vial, and a short-filled vial can return a purity result that is entirely accurate. The figure that answers the second question is measured mass against expected content — for Cartalax, this lot measured 103.2% of its labelled 20 mg. Both numbers are published for every lot, whichever way they fall.

The lot code printed on the vial matches the code on the certificate for Cartalax. Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.

Researchers who buy Cartalax in the United States through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.

Verify a batch code →

Lyophilized storage

−20 °C long-term; stable at room temperature in transit

After reconstitution

2–8 °C

Light

Protect from UV and direct light

Freeze-thaw

Avoid repeated cycles

Vehicle

Bacteriostatic water in most published protocols

Format

Lyophilized powder

Cartalax is supplied as lyophilized powder. In the dry state the material is comparatively stable, which is why it ships at ambient temperature without a cold chain; once reconstituted it is a peptide in solution and the handling constraints tighten considerably. At 3 residues it is short enough to be produced by solid-phase synthesis, and the published sequence on this page is what an identity assay is checked against.

Repeated freeze-thaw cycling is the handling error most likely to degrade material of this class, because each cycle concentrates solutes at the ice boundary. Where a protocol calls for the same vial across multiple sessions, the published literature generally describes aliquoting after reconstitution rather than re-freezing the whole volume.

Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.

Reconstitution calculator →

Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.